Novartis News | finanzen.ch

Novartis Aktie VALOR 1200526 / ISIN CH0012005267

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

23.02.16	Novartis Aktionäre genehmigen alle Anträge des Verwaltungsrats (GlobeNewswire)
19.02.16	Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML) (GlobeNewswire)
18.02.16	Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc. (GlobeNewswire)
12.02.16	Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA (GlobeNewswire)
11.02.16	Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim (GlobeNewswire)
31.01.16	Novartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination (GlobeNewswire)
27.01.16	Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations (GlobeNewswire)
27.01.16	Novartis erzielt 2015 eine kräftige Steigerung des Umsatzes und der Kern-gewinnmarge (kWk[1]); Pläne zur Wachstumsbeschleunigung bei Alcon und zur Straffung der Konzernaktivitäten bekannt gegeben (GlobeNewswire)
15.01.16	Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US (GlobeNewswire)
11.01.16	Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology (GlobeNewswire)
05.01.16	Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD (GlobeNewswire)
23.12.15	Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients (GlobeNewswire)
09.12.15	300 million child-friendly antimalarial treatments supplied without profit by Novartis (GlobeNewswire)
08.12.15	Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept (GlobeNewswire)
07.12.15	Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL (GlobeNewswire)
07.12.15	Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product (GlobeNewswire)
06.12.15	Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations (GlobeNewswire)
06.12.15	Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma (GlobeNewswire)
05.12.15	Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera (GlobeNewswire)
02.12.15	Novartis presents new data on targeted combination therapy at SABCS reinforcing commitment to breast cancer patients (GlobeNewswire)
30.11.15	Novartis highlights clinical advances at ASH 2015, underscoring leadership in hematology research (GlobeNewswire)
24.11.15	Novartis' heart failure medicine Entresto(TM) receives EU approval (GlobeNewswire)
23.11.15	Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis (GlobeNewswire)
18.11.15	Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA (GlobeNewswire)
17.11.15	FLAME study shows superiority of Novartis' Ultibro® Breezhaler® over Seretide® in reducing COPD exacerbations (GlobeNewswire)
15.11.15	Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting (GlobeNewswire)
08.11.15	Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients (GlobeNewswire)
08.11.15	New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis (GlobeNewswire)
04.11.15	Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors (GlobeNewswire)
29.10.15	Novartis Foundation and partners launch new hypertension program in Ghana (GlobeNewswire)
27.10.15	Novartis steigert die Kerngewinnmarge (kWk) im dritten Quartal kräftig, stärkt erneut die Pipeline und ist auf Kurs für die Jahresprognose (GlobeNewswire)
27.10.15	Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance (GlobeNewswire)
23.10.15	Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis (GlobeNewswire)
21.10.15	Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma (GlobeNewswire)
15.10.15	Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases (GlobeNewswire)
10.10.15	Novartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 years (GlobeNewswire)
08.10.15	Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years (GlobeNewswire)
05.10.15	Alcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery (GlobeNewswire)
02.10.15	FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept (GlobeNewswire)
30.09.15	Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis (GlobeNewswire)
28.09.15	Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist® (GlobeNewswire)
27.09.15	Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET (GlobeNewswire)
25.09.15	Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval (GlobeNewswire)
24.09.15	Novartis ernennt Dr. James E. Bradner zum Präsidenten der Novartis Institutes for BioMedical Research, da Mark Fishman in den Ruhestand tritt (GlobeNewswire)
24.09.15	Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires (GlobeNewswire)
24.09.15	Novartis lanciert "Novartis Access", ein Portfolio von erschwinglichen Medikamenten zur Behandlung von chronischen Erkrankungen in Ländern mit niedrigen Einkommen (GlobeNewswire)
24.09.15	Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries (GlobeNewswire)
18.09.15	Swissmedic approves Novartis' new heart failure medicine Entresto(TM) (GlobeNewswire)
07.09.15	Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH (GlobeNewswire)
04.09.15	Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myeloma (GlobeNewswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	4’097.00	0.71 %	K V
Nestle	88.52	0.42 %	K V
Roche Hldg G	259.90	0.27 %	K V
Swisscom	568.50	0.00 %	K V
Lonza Grp	560.00	-0.11 %	K V
UBS Group	26.09	-1.84 %	K V
Sonova Hldg	263.50	-1.90 %	K V
CieFinRichemont	156.65	-2.28 %	K V
Logitech Intl	69.14	-3.57 %	K V
Part Grp Hldg	1’071.00	-5.22 %	K V

mehr

23.05.25		Roche-Aktie steigt: Neuigkeiten zu Augenmedikament Susvimo und Krebsmittel Columvi - Kooperation in den USA
23.05.25		Bayer-Aktie etwas stärker: Empfehlung für 6-monatige Anwendung von Eylea 8mg - USA überraschend mild gegenüber Pestiziden
23.05.25		DAX 40-Wert Bayer-Aktie: So viel Verlust hätte eine Investition in Bayer von vor 5 Jahren bedeutet
23.05.25		SMI-Titel Roche-Aktie: So viel Verlust hätte ein Roche-Investment von vor 3 Jahren eingebracht
22.05.25		Sanofi-Aktie tiefer: Sanofi stärkt Neurologie-Portfolio mit Übernahme von Vigil Neuroscience
22.05.25		Bayer-Aktie gefragt: Bayer sichert sich China-Zulassung für neue Eylea-Dosierung
21.05.25		Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel hätten Anleger mit einem Investment in Johnson Johnson von vor 5 Jahren verdient